Carlos Liotta, MD
Sports Medicine · Tuscumbia, ALNPI 1528270790
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 178 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by GSK at 30.9% of the total. Reporting peaked in 2020 at $929 and has fallen 78.8% since, to $197 in 2025. That places this record below the midpoint for sports medicine clinicians in AL, where the typical reported total is $4,051.
Across 178 payments — averaging $22.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- Novo Nordisk$810
- AstraZeneca$742
- Amarin Pharma, Inc.$167
- AbbVie$152
- Merck$151
- plus $755 from 17 others
What the payments were for
- Food & beverage$4,017100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 71 | $1,240 |
| Novo Nordisk | 26 | $810 |
| AstraZeneca | 19 | $742 |
| Amarin Pharma, Inc. | 5 | $167 |
| AbbVie(2 entities) | 10 | $152 |
| Merck | 11 | $151 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $149 |
| Amgen | 2 | $112 |
| Pfizer | 2 | $107 |
| Lilly USA, LLC | 6 | $86 |
| Boehringer Ingelheim | 3 | $48 |
| Daiichi Sankyo Inc. | 3 | $45 |
| Johnson & Johnson | 2 | $31 |
| Galt Pharmaceuticals, LLC | 1 | $30 |
| Astellas Pharma US Inc | 1 | $23 |
| Phathom Pharmaceuticals, Inc. | 4 | $21 |
| Insulet Corporation | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Irhythm Technologies, Inc. | 1 | $14 |
| Ironwood Pharmaceuticals, Inc | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$206
- AIRSUPRA$121
- Ozempic$120
- RYBELSUS$109
- AREXVY$107
- BREZTRI$104
- BREZTRI AEROSPHERE$101
- Repatha$100
- Vascepa$100
How this compares
$4,017 in reported general payments places this provider in the 45th percentile of 108 sports medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 202 | $237,105 |
| FarxigaDapagliflozin Propanediol | 225 | $197,146 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 261 | $175,542 |
| JardianceEmpagliflozin | 108 | $108,218 |
| OzempicSemaglutide | 88 | $88,072 |
| VraylarCariprazine Hcl | 39 | $61,965 |
| EliquisApixaban | 79 | $61,441 |
| TrulicityDulaglutide | 52 | $59,071 |
| RelistorMethylnaltrexone Bromide | 21 | $47,818 |
| Xigduo XrDapaglifloz Propaned/Metformin | 52 | $37,220 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 37 | $36,082 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 41 | $34,277 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,503 | $34,268 |
| LinzessLinaclotide | 37 | $33,210 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 32 | $28,594 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $86 | $296,175254 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $742 | $236,196287 claims |
| GSKTrelegy Ellipta | $1,240 | $175,542261 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $48 | $144,301145 claims |
| AbbVieVraylar, Linzess | $152 | $95,17576 claims |
| Novo NordiskOzempic | $810 | $88,07288 claims |
| PfizerEliquis | $107 | $61,44179 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $149 | $47,81821 claims |
| Johnson & JohnsonXarelto | $31 | $26,79932 claims |
| MerckBelsomra | $151 | $26,76853 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 108 sports medicine providers in Alabama.
Other sports medicine in Tuscumbia
- Edward CainBirmingham$12.7M
- Daniel MatthewsDaphne$190K
- Mark RogersBirmingham$94K
- Amit MomayaBirmingham$77K
- Matthew SmithGuntersville$73K
- Christoper GarrettBirmingham$58K
- Jonathan IsbellHoover$55K
- James McMurtrieHuntsville$54K
- Reaves CrabtreeBirmingham$47K
- David AdkisonBirmingham$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.